Influence of Epilobium angustifolium and Serenoa repens extracts on cytochrome 2D2 and 3A1 expression level in rats

• Autorzy: Kujawski R. , Mrozikiewicz P. M. , Mikolajczak P. L. , Kuzio G. , Bogacz A. , Cichocka J. , Bartkowiak-Wieczorek J. , Grzeskowiak E. , Uzar I. , Bobkiewicz-Kozlowska T. , Czerny B.

Warianty tytułu

PL

Wpływ ekstraktów z Epilobium angustifolium i Serenoa repens na poziom ekspresji cytohromów 2D2 i 3A1 w modelu szczurzym

• Języki publikacji: EN

Abstrakty

EN

Benign prostatic hyperplasia (BPH) is a common disease affecting aging males. In recent years, as alternative strategy for the prevention and therapy of BPH, there is an growing interest in usage of plant derived remedies i.e. from Serenoa repens (sabal palm) and some plants from the Epilobium genus. The aim of this study was to investigate the influence of standardized Epilobium angustifolium L. and Serenoa repens extracts on expression level of CYP3A1 and CYP2D2 mRNAs in rats. Testosterone and standardized Epilobium angustifolium or commercial Serenoa repens extracts were given for 21 days to castrated male Wistar rats. The levels of CYP2D2 and CYP3A1 mRNAs expression were analyzed by real-time quantitative PCR using specific target primers. We have observed a slightly increased level of CYP2D2 mRNA in animals treated with testosterone and both plant extracts (by 4.6% in rats receiving Epilobium angustifolium extract and by 25.29% in animals treated with extract from Serenoa repens) and the CYP3A1 mRNA level by 11.02% in rats treated with Serenoa repens extract. In rats receiving E. angustifolium extract a 20.22% decrease of CYP3A1 mRNA expression level was observed. Results from our work showed that standardized plant extracts from Epilobium angustifolium and Serenoa repens have differentially influenced on CYP3A1 and CYP2D2 mRNA expression level in a rat liver.

PL

Łagodny rozrost gruczołu krokowego jest powszechnym schorzeniem występującym u starzejących się mężczyzn. W ostatnich latach wzrosło zainteresowanie roślinami leczniczymi należącymi do gatunku boczni piłkowanej (Serenoa repens) i rodzaju wierzbownica (Epilobium sp.), które mogą stać się alternatywną strategią profilaktyki i leczenia BPH. Celem pracy było ustalenie wpływu standaryzowanych wyciągów z Epilobium angustifolium i Serenoa repens na ekspresję cytochromów CYP3A1 i 2D2 u szczurów. Kastrowanym samcom szczurów rasy Wistar podawano przez okres 21 dni testosteron i badane, standaryzowane wyciągi roślinne. Zmiany poziomu ekspresji mRNA CYP3A1 i 2D2 mierzono techniką PCR w czasie rzeczywistym z użyciem starterów specyficznych dla cytochromów. Stwierdzono nieznaczne podwyższenie poziomu ekspresji mRNA CYP2D2 u zwierząt otrzymujących testosteron i oba wyciągi roślinne (podwyższenie o 4,6% u szczurów otrzymujących wyciąg z Epilobium angustifolium i o 25,29% u zwierząt otrzymujących wyciąg z Serenoa repens) i wzrost poziomu ekspresji mRNA CYP3A1 o 11,02% u zwierząt otrzymujących wyciąg z Serenoa repens. U szczurów otrzymujących wyciąg z Epilobium angustifolium stwierdzono obniżenie poziomu ekspresji mRNA CYP3A1 o 20,22%. Wyniki naszej pracy wykazały, że standaryzowane wyciągi z Epilobium angustifolium i Serenoa repens w zróżnicowany sposób wpływają na poziom transkrypcji CYP3A1 i CYP2D2 mRNA w wątrobie szczura.

• Wydawca: -
• Czasopismo: Herba Polonica
• Rocznik: 2010
• Tom: 56
• Numer: 4
• Opis fizyczny: p.39-51,fig.,ref.

Twórcy

autor

Kujawski R.

• Department of Pharmacology and Experimental Biology, Instytute of Natural Fibers and Medicinal Plants, Wojska Polskiego 71b, 60-630 Poznan, Poland

autor

Mrozikiewicz P. M.

autor

Mikolajczak P. L.

autor

Kuzio G.

autor

Bogacz A.

autor

Cichocka J.

autor

Bartkowiak-Wieczorek J.

autor

Grzeskowiak E.

autor

Uzar I.

autor

Bobkiewicz-Kozlowska T.

autor

Czerny B.

Bibliografia

• 1. Miano R, De Nunzio C, Asimakopoulos AD, Germani S, Tubaro A. Treatment options for benign prostatic hyperplasia in older men. Med Sci Monit 2008; 14(7):94- 102.
• 2. Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M. An overview on 5alpha-reductase inhibitors. Steroids 2010; 75(2):109-53.
• 3. Kiss A, Kowalski J, Melzig MF. Compounds from Epilobium angustifolium inhibit the specific metallopeptidases ACE, NEP and APN. Planta Med 2004; 70(10):919 -23.
• 4. Vitalone A, Bordi F, Baldazzi C, Mazzanti G, Saso L, Tita B. 2001. Anti-proliferative effect on a prostatic epithelial cell line (PZ-HPV-7) by Epilobium angustifolium L. Farmaco 2001;56(5-7):483-9.
• 5. Vitalone A, Guizzetti M, Costa LG, Tita B. Extracts of various species of Epilobium inhibit proliferation of human prostate cells. J Pharm Pharmacol 2003; 55(5):683-90.
• 6. Kiss A, Kowalski J, Melzig MF. Compounds from Epilobium angustifolium inhibit the specific metallopeptidases ACE, NEP and APN. Planta Med 2004;70(10):919- 23.
• 7. Schepetkin IA, Kirpotina LN, Jakiw L, Khlebnikov AI, Blaskovich CL, Jutila MA, Quinn MT. Immunomodulatory activity of oenothein B isolated from Epilobium angustifolium. J Immunol 2009; 183(10):6754-66.
• 8. Kosowicz J, Miskowiak B, Konwerska A, Belloni AS, Nussdorfer GG, Malendowicz LK. Pneumadin in the rat ventral prostate and its hormonal regulation. Hormon Metab Res 2004; 36:78-81.
• 9. Span PN, Voller MC, Smals AG, Sweep FG, Schalken JA, Feneley MR, Kirby RS. Selectivity of finasteride as an in vivo inhibitor of 5 alpha-reductase isoenzyme enzymatic activity in the humanprostate. J Urol 1999; 161:332–337.
• 10. Buck AC. Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J Ur ol 2004; 172(5):1792-9.
• 11. Gong EM, Gerber GS. Saw palmetto and benign prostatic hyperplasia. Am J Chin Med 2004;32(3):331- 338.
• 12. Fujita K. Food-drug interactions via human cytochrome P450 3A (CYP3A). Drug Metabol Drug Interact 2004; 20(4):195-217.
• 13. Imperato-McGinley J, Gautier T, Zirinsky K, Hom T, Palomo O, Stein E, Vaughan ED, Markisz JA, Ramirez de Arellano E, Kazam E. 1992. Prostate visualization studies in males homozygous andheterozygous for 5 a-reductase deficiency. J Clin Endocrinol Metab 1992; 89:293-300.
• 14. Habib FK, Ross M, Bayne CW, Grigor K, Buck AC, Bollina P, Chapman K. 1998. The localization andexpression of 5a-reductase type I and II mRNAs in human hyperplastic prostate and in prostate primary cultures. J Endocrinol 1998; 156:509-17.
• 15. Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC. The interaction between St John’s wort and an oral contraceptive. Clin Pharmacol Ther 2003; 74(6):525-35.
• 16. Greenblatt DJ, Leigh-Pemberton RA, von Moltke LL. In vitro interactions of water-soluble garlic components with human cytochromes p450. J Nutr 2006; 136(3 Suppl):806S-809S.
• 17. Henderson GL, Harkey MR, Gershwin ME, Hackman RM, Stem JS, Stresser DM. Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity. Life Sciences 1999; 15(3):209-14.
• 18. Uchida S, Yamada H, Li XD, Maruyama S, Ohmori Y, Oki T, Watanabe H, Umegaki K, Ohashi K, Yamada S. Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J Clin Pharmacol 2006; 46( 11):1290-8.
• 19. Delgoda R, Westlake AC. Herbal interactions involving cytochrome P450 enzymes: a mini review. Toxicol Rev 2004; 23(4):239-49.
• 20. Bonnet P, Reiter E, Bruyninx M. Benign prostatic hyperplasia and normal prostate aging: Differences in types I and II 5 alpha-reductase and steroid hormone receptor messenger ribonucleic acid (mRNA) levels, but not in insulin-like growth factor mRNA levels. J Clin Endocrinol Metab 1993; 77:1203-8.
• 21. Steenkamp V. Phytomedicines for the prostate. Fitoterapia 2003; 74:545-52.
• 22. Chow T, Imaoka S, Hiroi T, Funae Y. Developmental changes in the catalytic activity and expression of CYP2D isoforms in the rat liver. Drug Metab Dispos 1999; 27(2):188-92.
• 23. McVary KT. BPH: epidemiology and comorbidities. Am J Manag Car e 2006; 12(5 Suppl):122-8.
• 24. Ioannides C. Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica 2002; 32:451-78.
• 25. Steckelbroeck S, Heidrich DD, Stoffel-Wagner B, Hans VH, Schramm J, Bidlingmaier F, Kllingmuller D. Characterization of aromatase cytochrome P450 activity in the human temporal lobe. J Clin Endocrinol Metab 1999; 84(8):2795-801.
• 26. Thum T, Borlak J. Testosterone, cytochrome P450, and cardiac hypertrophy. FASEB J 2002; 16(12):1537-49.
• 27. Markowitz JS, Donovan JL, Devane Cl, Taylor RM, Ruan Y, Wang JS, Chavin KD. Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers. Clin Pharmacol Ther 2003; 74(6):536-42.
• 28. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J, Khan IA, Edwards DJ, Shah A. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 2004; 76(5):428-40.
• 29. Yale SH, Glurich I. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. J Altern Complement Med 2005; 11(3):433-9.
• 30. Delaforge M. Importance of metabolism in pharmacological studies: possible in vitro predictability. Nucl Med Biol 1998; 25(8):705-9.
• 31. Leskela S, Honrado E, Montero-Conde C, Landa I, Cascon A, Leton R, Talavera P, Cozar JM, Concha A, Robledo M, Rodriguez-Antona G. Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer. Endocr Relat Cancer 2007; 14(3):645-54.
• 32. Javvosi Z, Cooper KO, Thomas PE. Brain cytochrome P450 and testosterone metabolism by rat brain subcellular fractions: presence of cytochrome P450 3A immunoreactive protein in rat brain mitochondria. Arch Biochem Biophys 1992;298(1):265-70.
• 33. Mäenpää J, Pelkonen O, Cresteil T, Rane A. The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol 1993; 44(1):61-7.
• 34. Gemzik B, Green J, Parkinson A. Hydroxylation of 5 alpha-androstane-3 beta,17 beta-diol by rat prostate microsomes: effects of antibodies and chemical inhibitors of cytochrome P450 enzymes. Arch Biochem Biophys 1992; 296(2):356-65.
• 35. Nallani SC, Genter MB, Desai PB. Increased activity of CYP3A enzyme in primary cultures of rat hepatocytes treated with docetaxel: comparative evaluation with paclitaxel. Cancer Chemother Pharmacol 2001; 48(2):115-22.
• 36. Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzales FJ, Gelboin HV. Role of human cytochrome 450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 1998; 8(5):391-401.
• 37. Dai D, Bai R, Hodgson E, Rose RL. Cloning, sequencing, heterologous expression, and characterization of murine cytochrome P450 3a25*(Cyp3a25), a testosterone 6beta-hydroxylase. J Biochem Mol Toxicol 2001; 15(2):90-99.

Uwagi

rekord w opracowaniu